КЕТОГЕННАЯ ДИЕТА — НЕМЕДИКАМЕНТОЗНЫЙ СПОСОБ ЛЕЧЕНИЯ ЭПИЛЕПСИИ
Аннотация
статье представлены данные о возможностях применения кетогенной диеты у пациентов с эпилепсией. Актуальность темы обусловлена тем, что медикаментозное лечение данного недуга приводит к купированию приступов менее чем в 70% случаев, в связи с чем существует необходимость использования альтернативных методов терапии. Проанализированы экспериментальные и клинические данные о результатах применения кетогенной диеты, а также рассмотрены механизмы, лежащие в основе ее клинических эффектов.
Литература
Ерофеев Н.П., Радченко В.Г., Селиверстов П.В. Клиническая физиология толстой кишки. Механизмы действия короткоцепочечных жирных кислот в норме и при патологии. СПб.; 2012.
Воронкова К.В. Эпилепсии в практике педиатра. Практика педиатра. 2015; 1: 54–63.
Гузева О.В., Гузева В.И., Гузева В.В. и др. Результаты оценки качества лечения и жизни детей с эпилепсией. Педиатр. 2017; 2.
Beghi E., Giussani G., Abd-Allah F.A. et al. Global, Regional, and National Burden of Epilepsy, 1990–2016: A Systematic Analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019; 18: 357–75.
Dahlin M., Prast-Nielsen S. The gut microbiome and epilepsy. EBioMedicine. 2019; 44: 741–6.
Kobow K., Blümcke I. Epigenetics in Epilepsy. Neurosci Lett. 2018; 667: 40–6.
Wheless J.W. History of the ketogenic diet Epilepsia. 2008; 49(8): 3–5.
Meira I. D’Andrea, Romão T.T., Pires do Prado H.J. et al. Ketogenic Diet and Epilepsy: What We Know So Far. Front. Neurosci. 2019; 13: 5.
Lobo F., Haase J., Brandhorst S. The Effects of Dietary Interventions on Brain Aging and Neurological Diseases. Nutrients. 2022; 14(23): 5086.
Dyńka D., Kowalcze K., Paziewska A. The Role of Ketogenic Diet in the Treatment of Neurological Diseases. Nutrients. 2022; 14(23): 5003.
Клинические рекомендации. Эпилепсия и эпилептический статус у взрослых и детей. МЗ РФ. 2022.
Kossoff E.H., Zupec-Kania B.A., Auvin S. et al. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open. 2018; 3(2): 175–92.
Барановский А.Ю. Диетология: руководство. СПб.: Питер; 2012.
Педиатрия. Национальное руководство. Под ред. А.А. Баранова. М.: ГЭОТАР-Медиа. 2009; 1.
Ramm-Pettersen A., Selmer K.K., Nakken K.O. Glucose transporter protein type 1 (GLUT-1) deficiency syndrome. Tidsskr Nor Laegeforen. 2011; 131(8): 828–31.
Лукьянова Е.Г., Айвазян С.О., Осипова К.В. и др. Опыт применения кетогенной диеты у пациентов с синдромом дефицита транспортера глюкозы 1 типа (клиническое наблюдение). Журнал неврологии и психиатрии им. С.С.Корсакова 2015; 115(5-2): 53–60.
van der Louw E., van den Hurk D., Neal E. et al. Ketogenic diet guidelines for infants with refractory epilepsy. Eur J Paediatr Neurol. 2016; 20(6): 798–809.
Ye F., Li X.J., Jiang W.L. et al. Efficacy of and patient compliance with a ketogenic diet in adults with intractable epilepsy: a meta-analysis. J Clin Neurol. 2015; 11(1): 26–31.
Martin K., Jackson C.F., Levy R.G., Cooper P.N. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev. 2016.
Neal E.G., Chaffe H., Schwartz R.H. et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008; 7(6): 500–6.
Lambrechts DAJE., de Kinderen RJA., Vles JSH. et al. A randomized controlled trial of the ketogenic diet in refractory childhood epilepsy. Acta Neurol Scand. 2017; 135(2): 231–9.
Zare M., Okhovat A.A., Esmaillzadeh A. et al. Modified Atkins diet in adult with refractory epilepsy: A controlled randomized clinical trial. Iran. J. Neurol. 2017; 16: 72–7.
Liu H., Yang Y., Wang Y. et al. Ketogenic diet for treatment of intractable epilepsy in adults: A meta-analysis of observational studies. Epilepsia Open. 2018; 3(1): 9–17.
Лукьянова Е.Г., Айвазян С.О., Осипова К.В. и др. Когнитивные и моторные функции у детей с фармакорезистентными формами эпилепсии, находящихся на кетогенной диете. Эпилепсия и пароксизмальные состояния. 2016; 8(1): 37–42.
Айвазян С.О., Ширяев Ю.С. Современные методы лечения пациентов с фармакорезистентной эпилепсией, доступные в РФ. Эпилепсия и пароксизмальные состояния. 2016; 8(1): 22–8.
Айвазян С.О., Лукьянова Е.Г., Ширяев Ю.С. Современные возможности лечения фармакорезистентной эпилепсии у детей. Эпилепсия и пароксизмальные состояния. 2014; 6(1): 34–42.
Olson C.A., Iñiguez A.J., Yang G.E. et al. Alterations in the gut microbiota contribute to cognitive impairment induced by the ketogenic diet and hypoxia. Cell Host Microbe. 2021; 29(9): 1378–92.
Verrotti A., Iapadre G., Di Francesco L. et al. Diet in the Treatment of Epilepsy: What We Know So Far. Nutrients. 2020; 12(9): 2645.
Mahapatra S., Nagpal R., Marya C.M. et al. Gut Mycobiome and Its Interaction With Diet, Gut Bacteria and Alzheimer's Disease Markers in Subjects With Mild Cognitive Impairment: A Pilot Study. EBioMedicine. 2020; 59: 102950.
Guzel O., Uysal U., Arslan N. Efficacy and Tolerability of Olive Oil-Based Ketogenic Diet in Children With Drug-Resistant Epilepsy: A Single Center Experience From Turkey. Eur J Paediatr Neurol. 2019; 23: 143–51.
Тюльганова Д.А., Насаев Ш.Ш., Чугреев И.А. и др. Механизмы действия кетогенной диеты. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2018; 118(10-2): 72–5.
Sondhi V., Agarwala A., Pandey R.M. et al. Efficacy of Ketogenic Diet, Modified Atkins Diet, and Low Glycemic Index Therapy Diet Among Children With Drug-Resistant Epilepsy: A Randomized Clinical Trial. JAMA Pediatr. 2020; 174: 944–51.
Ding M., Lang Y., Shu H. et al. Microbiota-Gut-Brain Axis and Epilepsy: A Review on Mechanisms and Potential Therapeutics. Front Immunol. 2021; 12: 742449.
Rogawski M.A., Löscher W., Rho J.M. Mechanisms of action of antiseizure drugs and the ketogenic diet. Cold Spring Harb Perspect Med. 2016; 6(5).
Иванникова Е.В., Алташина М.В., Трошина Е.А. Кетогенная диета: история возникновения, механизм действия, показания. Проблемы эндокринологии. 2022; 68(1): 49–72.
Yuskaitis C.J., Modasia J.B., Schrötter S. et al.
DEPDC5-dependent mTORC1 signaling mechanisms are critical for the anti-seizure effects of acute fasting. Cell Rep. 2022; 40: 111278.
Greene A.E., Todorova M.T., McGowan R., Seyfried T.N. Caloric restriction inhibits seizure susceptibility in epileptic EL mice by reducing blood glucose. Epilepsia. 2001; 42: 1371–8.
Mantis J.G., Centeno N.A., Todorova M.T. et al. Management of multifactorial idiopathic epilepsy in EL mice with caloric restriction and the ketogenic diet: Role of glucose and ketone bodies. Nutr. Metab. 2004; 1: 11.
Landgrave-Gómez J., Mercado-Gómez O.F., Vázquez-García M. et al. Anticonvulsant Effect of Time-Restricted Feeding in a Pilocarpine-Induced Seizure Model: Metabolic and Epigenetic Implications. Front. Cell Neurosci. 2016; 10: 7.
Taha A.Y., Burnham W.M., Auvin S. Polyunsaturated Fatty Acids and Epilepsy. Epilepsia. 2010; 51: 1348–58.
Bough K.J., Rho J.M. Anticonvulsant Mechanisms of the Ketogenic Diet. Epilepsia. 2007; 48: 43–58.
Zimmer L., Delpal S., Guilloteau D. et al. Chronic N-3 Polyunsaturated Fatty Acid Deficiency Alters Dopamine Vesicle Density in the Rat Frontal Cortex. Neurosci Lett. 2000; 284: 25–8.
Bahagat K.A., Elhady M., Aziz A.A. et al. Omega-6/Omega-3 Ratio and Cognition in Children With Epilepsy. Pediatr (Engl Ed). 2019; 91: 88–95.
Sohouli M.H., Razmpoosh E., Zarrati M., Jaberzadeh S. The Effect of Omega-3 Fatty Acid Supplementation on Seizure Frequency in Individuals With Epilepsy: A Systematic Review and Meta-Analysis. Nutr Neurosci. 2021; 30: 1–10.
Rho J.M., Shao L.R., Stafstrom C.E. 2-Deoxyglucose and Beta-Hydroxybutyrate: Metabolic Agents for Seizure Control. Front. Cell Neurosci. 2019; 13: 172.
Olson C.A., Vuong H.E., Yano J.M. et al. The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet. Cell. 2018; 173(7): 1728–41.
Xie G., Zhou Q., Qiu C.Z. et al. Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy. World J. Gastroenterol. 2017; 23: 6164–71.
Amlerova J., Šroubek J., Angelucci F., Hort J. Evidences for a Role of Gut Microbiota in Pathogenesis and Management of Epilepsy. Int J Mol Sci. 2021; 22(11): 5576.
Rutsch A., Kantsjö J.B., Ronchi F. The Gut-Brain Axis: How Microbiota and Host Inflammasome Influence Brain Physiology and Pathology. Front Immunol. 2020; 11: 604179.
Gershon M.D. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2013; 20: 14–21.
Glebov K., Löchner M., Jabs R. et al. Serotonin stimulates secretion of exosomes from microglia cells. Glia. 2015; 63: 626–34.
Rothhammer V., Borucki D.M., Tjon E.C. et al. Microglial control of astrocytes in response to microbial metabolites. Nature. 2018; 557: 724–8.
Sudo N., Chida Y., Aiba Y. et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice J Physiol . 2004; 558(Pt 1): 263–75.
Cryan J.F., O’Riordan K.J., Cowan CSM. The Microbiota-Gut-Brain Axis. Physiol Rev. 2019; 99(4): 1877–2013.
Chen Y., Xu J., Chen Y. Regulation of Neurotransmitters by the Gut Microbiota and Effects on Cognition in Neurological Disorders Nutrients. 2021; 13(6): 2099.
Cowan CSM., Hoban AE., Ventura-Silva AP. et al. Gutsy Moves: The Amygdala as a Critical Node in Microbiota to Brain Signaling. Bioessays. 2018; 40(1).
Galland L. The Gut Microbiome and the Brain. J Med Food. 2014; 17: 1261–72.
Frost G., Sleeth M.L., Sahuri-arisoylu M. et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun. 2014; 5: 1–11.
Li D., Bai X., Jiang Y., Cheng Y. Butyrate Alleviates PTZ-Induced Mitochondrial Dysfunction, Oxidative Stress and Neuron Apoptosis in Mice via Keap1/Nrf2/HO-1 Pathway. Brain Res Bull. 2021; 168: 25–35.
Oleskin A.V., Shenderov B.A. Neuromodulatory effects and targets of the SCFAs and gasotransmitters produced by the human symbiotic microbiota. Microb Ecol Health Dis. 2016; 2235: 1–12.
Nankova B.B., Agarwal R., MacFabe D.F., La Gamma E.F. Enteric Bacterial Metabolites Propionic and Butyric Acid Modulate Gene Expression, Including CREB-Dependent Catecholaminergic Neurotransmission, in PC12 Cells — Possible Relevance to Autism Spectrum Disorders. PloS One. 2014; 9: e103740.
Tolhurst G., Heffron H., Lam Y.S. et al. Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR2. Diabetes. 2012; 61: 364–71.
Everard A., Lazarevic V., Gaïa N. et al. Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity. ISME J. 2014; 8: 2116–30.
Caspani G., Swann J. Small talk: Microbial metabolites involved in the signaling from microbiota to brain. Curr. Opin. Pharmacol. 2019; 48: 99–106.
